Home › Compare › AKAAF vs ABBV
AKAAF yields 4.64% · ABBV yields 3.06%● Live data
📍 AKAAF pulled ahead of the other in Year 1
Combined, AKAAF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of AKAAF + ABBV for your $10,000?
Aker ASA operates as an industrial investment company in Norway, the European Union, North America, South America, Asia, and internationally. It operates in two segments, Industrial Holdings and Financial Investments. The company engages in the exploration and production of oil and gas; provides solutions, products, and services to the energy industry; develops and delivers technologies to drilling market; holds oil reserves; and harvests, develops, markets, and sells krill-based ingredients and product for nutraceutical, aquaculture, and animal feed applications. It also focuses on renewable energy and green technologies; builds and operates sea-based salmon farming; offers Cognite Data Fusion that collects, processes, and facilitates big data for its industry customers; designs, constructs, and leases vessels; owns and operates supply-vessels, anchor handling vessels, and construction service vessels; trades in financial instruments; operates platform for venture capital in industrial technology; develops real estate and software; acts as an investment manager; and invests in bitcoin, and projects and companies throughout the bitcoin ecosystem. The company was founded in 1841 and is based in Lysaker, Norway. Aker ASA is a subsidiary of TRG Holding AS.
Full AKAAF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.